Pharmacological activation of the circadian component REV-ERB inhibits HIV-1 replication
H. Borrmann, R. Davies, M. Dickinson, I. Pedroza-Pacheco, M. Schilling, A. Vaughan-Jackson, W. James, P. Balfe, P. Borrow, J. A. McKeating, X. Zhuang
This study shows that REV-ERB agonists inhibit HIV-1 replication by suppressing its promoter activity in multiple cell types.
Scientific Reports · Aug 6, 2020Peer-reviewedMicrobiology